ONCY Oncolytics Biotech, Inc.

$ONCY Instead of being a drug for just one cancer, pelareorep's ability to act as a core combination partner allows it to serve as a platform for multiple distinct indications: - Anal and HPV-driven Cancers: Clinical trial data highlights its potential as a backbone immunotherapy paired with checkpoint inhibitors (like atezolizumab) to treat squamous cell anal cancer, with plans to expand into head and neck cancers. - Colorectal Cancer: It is being evaluated in combination with standard chemotherapies and targeted agents (like FOLFIRI and bevacizumab). - Pancreatic Cancer: It is used to prime pancreatic tumors to make them more receptive to immunotherapy and chemo cocktails. - Breast & Liver Cancers: Clinical evidence demonstrates its ability to transform the microenvironment of breast and liver tumors so that other immunotherapies can actually work.

$ONCY Yes, of course. Hedge fund pumping Moderna raising MRNA share price to /share and market cap $90 Billion. Very promising for ONCY and its ROV acqusition valuation in the range of $25-$45 Billion. When evaluated strictly as standalone commercial products and scalability, Moderna's mRNA cancer vaccine acts as a bespoke boutique service, whereas ONCY’s pelareorep functions as a mass-market utility. Pelareorep delivers superior clinical utility in multi-billion-dollar RAS activated, GI and HPV cancer indications without any of the crippling financial, manufacturing, or deep-freeze logistical burdens that hold Moderna back.

$ONCY Garbage investment. I'm so exhausted with owning this stock. 1) Some say it's being shorted or manipulated 2) Some say it's being bought out for $25-45 billion Let's cut to the chase. This has done nothing in the 17 months since Jared Kelly took over. Thompson = Coffey = Kelly Same song and dance for 28 years. I was fooled. I'm hoping it changes in a positive direction

$ONCY When Merck bids $25-$30+ billion, it isn't just buying one drug; it is acquiring a technological platform. Platforms targeting complex mutations provide Merck with an expansive pipeline capable of treating multiple distinct indications. This drastically scales up their commercial opportunities, allowing the company to forecast multi-billion dollar returns well into the mid-2030s.

$ONCY no hedge fund is wasting their time on oncy, let alone any similar micro cap stock, because the structural math of their funds makes it literally impossible or inefficient to participate. And shorting a penny stock/micro cap is a uniquely terrible (stupid) risk to reward trade for a professional hedge fund because the upside is capped and the risk is uncapped.

$ONCY not-able-x is not a "long" and has admitted to not owning a long position. It is a LifeSci firm paid pumper. Saxy, well the jury is out on him.

$ONCY Notable is taking standard institutional filings (like Anson’s 13G/A warrant holdings) and spinning them into an elaborate cinematic narrative. The reality is far more mundane: institutional funds manage capital across various hedging and arbitrage structures, while Notable is turning routine portfolio management into wild fiction to cope with a depressed stock price.

$ONCY How convenient for a acquirer to have one stop shopping with a drug that handles several cancers ... IS IT POSSIBLE THAT JK HAS A BIG PRICE TAG ....otherwise this could have been sold already !! for peanuts ..... that last mile in a marathon is always the toughest

$ONCY we’ve finally reached stage 3 on this message board: pure nihilism, historical revisionism, and existential despair. Just as some push conspiracy theories which are detached from the reality of financial modeling, others call for an inquisition which detaches from operational reality. Oncy remains a high risk, microcap binary play dependent on clinical trial endpoints and partnership execution, independent of petulant message board mood swings. If and when the part A data hits, it will soon after be either the greatest investment of your lives or the worst. But at least let the data drop.

$ONCY It almost feels like stock-market gentrification—retail holders get worn down and pushed out, potentially leaving larger investors to benefit if the company succeeds. I’m not going anywhere!

$ONCY as discussed many times, for the penny stock with a $60m MC, the best case scenario is a very modest biobucks deal. Think $25m upfront & a total of $250m in milestones. Everyone here would be elated to receive such a deal.

$ONCY The fully diluted share count as of August 2026 is 156 million ...therefore for every $1B buyout it comes to $6.40 .... so a $5B price tag comes to $32 a share .... this is a conservative figure

$ONCY according to a discussion on Yahoo finance Oncy has until January 19th to get back to a dollar and hold said price for 10 days to be Nasdaq compliant. The PR firm paid pumper (known as Yfuser, S,N, L, Lou & other aliases on Yahoo) has opined that there's nothing to worry about as Oncy is guaranteed to be acquired or partnered by then. Hopefully it's right for once, but if not expect a public apology.

$ONCY Why pelareorep is unique. Dr. Richard Vile: The Central Hub of the Mayo Clinic Dr. Richard Vile is not just a researcher; he holds multiple strategic positions at the pinnacle of oncological research at the Mayo Clinic and Oncolytics: • His roles at the Mayo Clinic: He serves as the Director of the Immuno-Oncology Program and Co-Director of the Gene and Virus Therapy Program at the Mayo Clinic.His role at Oncolytics: He is a member of the Scientific Advisory Board at Oncolytics Biotech. As a long-standing collaborator of the biotech company, he knows pelareorep intimately.His recent work: His laboratory at the Mayo Clinic led cutting-edge research (notably presented at the ASCO annual meeting) demonstrating how pelareorep manages to "wake up" the immune system by multiplying pre-existing immune cells against gastrointestinal tumors. The Technological "Bridge" to Big Pharma / GSK Influence .......

$ONCY This GOBLET Cohort 4 update is a clear step forward for pelareorep in second-line squamous cell anal cancer. The roughly 15-month median duration of response meaningfully exceeds the historical 9.5-month benchmark for approved checkpoint monotherapy, every responding patient has survived beyond a year (with several past two years), and median overall survival still hasn’t been reached.  Looking ahead, watch for a potential registrational study in SCAC supported by the existing Fast Track designation and recent FDA clarity, continued maturation of the survival curves, a possible partnership to accelerate development, and early moves into other HPV-driven cancers such as head and neck—where pelareorep already has encouraging single-agent signals and a combination study is on the near-term radar. These data strengthen the case for pelareorep as a backbone immunotherapy in this setting.

$ONCY you do realize your $25B- $45B ROV has a starting price of $160 a share ...... not even big Pharma would go out on the limb .... My top max value would be $40-50 ..... of course I wish you are right

$ONCY My buyout revision Conservative (good but not transformative data): $1.5–3B → $8–18/sh Base (strong CRC + reg path): $3–6B → $15–35/sh Optimistic (multi-indication + platform premium): $6–10B → $30–55/sh Extreme bull: $10B+ → $50–70+/sh Assumes ~160–200M diluted shares

$ONCY indicates new translational data from its pelareorep study in HPV-driven anal cancer, showing immune-system impact.

$ONCY 🏥 Oncolytics Biotech announced new translational data from an ongoing anal cancer study showing pelareorep more than doubled immune activation in nearly all patients after one cycle and substantially increased HPV-16-specific T cells and tumor-infiltrating lymphocytes when combined with a checkpoint inhibitor. Curated for market relevance

$ONCY Jared Kelly has been at the helm of Oncy for 17 months—a company that was effectively already dead (trading at $0.34 before his arrival was announced). He took the risk, fully aware that if he were lucky enough to find a buyer, he would become very wealthy (let’s not forget that his contract entitled him to 2% of the total sale price). He tried, but unfortunately failed—much like his predecessors—because Big Pharma simply does not believe in Pela, a product that is already 30 years old. Now, the future is full of questions. A reverse split is inevitable for the company’s survival, but the major dilemma is: what is the point? If no one believes in Pela, wouldn't it be better to shut down the project once and for all—a project that has dragged on for 30 years without ever yielding results—rather than continuing to pay out massive salaries while effectively picking the pockets of the shareholders?